alexa Induction Of De Novo HCV Core-specific Cell-;mediated Immune Responses And Enhancement Of Neutralizing Antibodies Response By CIGB-230, A DNA-based Vaccine Candidate, On Triple Therapy With IFN-α Plus Ribavirin
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Amador-Canizares Y, Martinez-Donato G, Alvarez-Lajonchere L, Vasallo C, Dausa M, Aguilar-Noriega D, Valenzuela C, Raices I, Dubuisson J, Wychowski C, Cinza-Estevez Z, Castellanos M, Nunez M4, Armas A, Gonzalez Y J, Reve I, Guerra I1, Perez-Aguiar A and Duenas-Carrera S
Accepted Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.022
Abstract
C IGB-230 is a vaccine candidate based on the mixture of a DNA plasmid, expressing HCV structural proteins, with recombinant HCV core protein. In this work CIGB-230 was administered in different schedules regarding IFN-α plus ribavirin therapy in a Phase II clinical trial. Paired serum and PBMC samples from baseline and end of treatment were analyzed. Data on virological and histological response and their association with immune variables are also provided. From week 12 to week 48, all groups of patients showed a significant reduction in mean leukocyte counts. Statistically significant decrements in antibody titres were frequent, but only individuals immunized with CIGB-230 as early add-on sustained the core-IgG response, and the neutralizing antibody response was enhanced only in patients receiving CIGB-230. Cell-mediated immune responses also tended to decline, but significant decrements in IFN-γ secretion and total absence of core-specific lymphoproliferation were exclusive of the control group. Only CIGB-230-immunized individuals showed de novo induced lymphoproliferative responses against the structural antigens. Importantly, it was demonstrated that the quality of CIGB- 230-induced immune response depends on number of doses and timing of administration in relation to the antiviral therapy. Specifically, the administration of six doses of CIGB-230 as late add-on to therapy increased the neutralizing antibody activity and the de novo core-specific IFN-γ secretion, with a favorable impact in the virological response. In conclusion, CIGB-230, combined with IFN-α-based therapy, modifies the immune response in chronic patients. These evidences shed light in the design of more effective therapeutic vaccine interventions against HCV
Biography
Amador-Canizares Y has completed her PhD at the age of 33 years from Havana University. She is a young investigator at the Hepatitis C Section, of the Vaccines Department, at the Center for Genetic Engineering and Biotechnology, a leading biotechnology institute at Havana, Cuba. She has published more than 10 papers in reputed journals. She is member of the Cuban Societies of Hepatology and Immunology. She received 4 awards at the Cuban Academy of Sciences.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthca[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords